Results obtained with combination therapy of VM-26, natulan and prednisolone in generalized Hodgkin's disease.
By evaluating the results obtained in 50 patients the authors stated that VM-26 given in combination with Natulan and Prednisolone is a drug of value in the therapy of generalized Hodgkin's disease. It cause milder side effects than drugs previously used in combination therapy. Complete or partial remissions were obtained in 84% of patients treated. 75% of the therapy-resistant cases proved to be Hodgkin's sarcoma by the postmortem examination. Remission lasted longer in stage III than in stage IV and the previously untreated patients responded better than the treated one. Definite correlation could not be revealed between histologic type and duration of remission.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use*; D011859:Radiography; D013713:Teniposide / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D011344:Procarbazine; D013713:Teniposide; D011239:Prednisolone; D011034:Podophyllotoxin